Saturday, November 2, 2024
HomeTagsAlaunos Therapeutics

Alaunos Therapeutics

Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T

Precigen, Inc, a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, announced the amendment...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics